Zeng B, Prasan A, Fung K C, Solanki V, Bruce D, Freedman S B, Brieger D
Department of Cardiology, Concord Hospital, Vascular Biology Laboratory, ANZAC Research Institute, University of Sydney, Australia.
Intern Med J. 2005 Jun;35(6):331-5. doi: 10.1111/j.1445-5994.2005.00822.x.
Matrix metalloproteinases (MMP-9 and MMP-2) have been implicated in development of atherosclerosis and plaque rupture in acute coronary syndromes (ACS).
To determine the relationship between circulating MMPs and symptomatic coronary artery disease.
Plasma levels of MMP-9 and MMP-2 were measured in patients with ACS, stable angina (SA) and in controls, using a quantitative gelatin zymography. These measurements were correlated with markers of systemic inflammation (hs-CRP) in all subjects and myocardial injury (troponin T) in patients with ACS.
Plasma MMP-9 in ACS was greater than in SA, and was greater in SA than in controls (P < 0.01 ACS vs SA and controls, P < 0.01 SA vs control). Plasma MMP-2 was significantly greater in ACS than SA or controls (P < 0.01 vs SA and controls). There was strong overall relationship between hs-CRP and MMP-9 (r = 0.65, P < 0.0001) driven by a significant relationship in ACS patients (r = 0.58, P = 0.02), as there was no significant association in SA or controls. A weaker overall correlation was found between hs-CRP and MMP-2 (r = 0.39, P = 0.02), but no significant relationship was present for either of the two patient subgroups or controls. There was no correlation between levels of troponin T and MMP-9, MMP-2 or hs-CRP in ACS patients.
Quantitative gelatin zymography identifies increased circulating levels of MMP-9 and MMP-2 in patients with symptomatic coronary disease. MMP-9 and MMP-2 are higher in ACS than SA patients and might have use as markers of plaque rupture or instability. The strong relationship between MMP-9 and hs-CRP in ACS patients suggests MMP-9 might be an additional marker and/or consequence of the inflammatory component in ACS.
基质金属蛋白酶(MMP - 9和MMP - 2)与动脉粥样硬化的发展以及急性冠状动脉综合征(ACS)中的斑块破裂有关。
确定循环中的基质金属蛋白酶与有症状冠状动脉疾病之间的关系。
采用定量明胶酶谱法测定ACS患者、稳定型心绞痛(SA)患者及对照组血浆中MMP - 9和MMP - 2的水平。在所有受试者中,这些测量值与全身炎症标志物(hs - CRP)相关;在ACS患者中,与心肌损伤标志物(肌钙蛋白T)相关。
ACS患者血浆MMP - 9水平高于SA患者,SA患者高于对照组(ACS与SA及对照组相比,P < 0.01;SA与对照组相比,P < 0.01)。ACS患者血浆MMP - 2水平显著高于SA患者或对照组(与SA及对照组相比,P < 0.01)。hs - CRP与MMP - 9之间存在很强的总体相关性(r = 0.65,P < 0.0001),这主要由ACS患者中的显著相关性驱动(r = 0.58,P = 0.02),因为在SA患者或对照组中无显著关联。hs - CRP与MMP - 2之间的总体相关性较弱(r = 0.39,P = 0.02),但在两个患者亚组或对照组中均无显著关系。ACS患者中肌钙蛋白T水平与MMP - 9、MMP - 2或hs - CRP之间无相关性。
定量明胶酶谱法显示有症状冠心病患者循环中MMP - 9和MMP - 2水平升高。ACS患者的MMP - 9和MMP - 2高于SA患者,可能用作斑块破裂或不稳定的标志物。ACS患者中MMP - 9与hs - CRP之间的强关系表明MMP - 9可能是ACS中炎症成分的额外标志物和/或结果。